Skip to main content
Premium Trial:

Request an Annual Quote

Castle Biosciences Gains New York State Approval for Pittsburgh Laboratory

NEW YORK – Castle Biosciences said Tuesday that it has received a clinical laboratory permit from the New York State Department of Health for its lab in Pittsburgh, allowing it to perform tests for patients and physicians in the state at that facility, in addition to its Phoenix headquarters, which received its permit in early 2018.

Both laboratories are also accredited by the College of American Pathologists and are Clinical Laboratory Improvement Amendments (CLIA)-certified, which enables clinical testing in most other US states.

Castle Chief Operating Officer Kristen Oelschlager said in a statement that "successful completion of the rigorous New York State licensure process" reflects the company's commitment to serve patients "through high-quality molecular tests," which include assays for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions.

The firm said that it doubled the size of its Pittsburgh operations earlier this year in a move to a new, 20,000 square-foot laboratory, providing room for it to continue to scale its operations. The firm now operates in more than 52,000 square feet across its two facilities in Pittsburgh and Phoenix.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.